US Pharma MarketingThe post EASD 2026: Roche’s enicepatide shows 22.7% placebo-adjusted weight loss at 48 weeks appeared first on Clinical Trials Arena.
EASD 2026: Roche's enicepatide shows 22.7% placebo-adjusted weight loss at 48 weeks
Key opinion leaders interviewed by GlobalData viewed enicepatide's dual-receptor mechanism as a significant advancement over single-target GIP agonism. Key opinion leaders interviewed by GlobalData viewed enicepatide's dual-receptor mechanism as a significant advancement over single-target GIP agonism. Roche presented the data at EASD in Milan, Italty. Credit: HJBC / Shutterstock.com Unlock FREE Access to Premium Content Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free Clinical Trials Arena profile, you can: Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise. Hard data…
Key opinion leaders interviewed by GlobalData viewed enicepatide's dual-receptor mechanism as a significant advancement over single-target GIP agonism.
Source: Clinical Trials Arena